Structure Therapeutics (NASDAQ:GPCR) Now Covered by Morgan Stanley

Equities researchers at Morgan Stanley began coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report issued on Monday, Briefing.com reports. The firm set an “overweight” rating and a $118.00 price target on the stock. Morgan Stanley’s target price points to a potential upside of 181.49% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 16th. JMP Securities dropped their price target on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research note on Friday, August 9th. Finally, BMO Capital Markets raised their price objective on Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, June 7th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $88.33.

Structure Therapeutics Price Performance

Shares of GPCR stock opened at $41.92 on Monday. The stock’s fifty day moving average price is $37.97 and its 200 day moving average price is $39.61. Structure Therapeutics has a 1-year low of $26.61 and a 1-year high of $75.02. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -54.44 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. As a group, equities research analysts anticipate that Structure Therapeutics will post -0.86 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. Boxer Capital LLC acquired a new stake in Structure Therapeutics in the fourth quarter valued at approximately $16,304,000. Avoro Capital Advisors LLC grew its stake in Structure Therapeutics by 133.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock valued at $95,107,000 after acquiring an additional 1,333,333 shares during the period. Octagon Capital Advisors LP purchased a new stake in Structure Therapeutics in the 4th quarter worth $16,875,000. Bellevue Group AG raised its position in Structure Therapeutics by 2,858.7% during the first quarter. Bellevue Group AG now owns 363,926 shares of the company’s stock worth $15,598,000 after acquiring an additional 351,626 shares during the period. Finally, Capital International Investors purchased a new position in Structure Therapeutics during the fourth quarter valued at $34,647,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.